Home › Funds › Bain Capital Life Sciences Investors, LLC › CCCC
Bain Capital Life Sciences Investors, LLC position in CCCC
C4 THERAPEUTICS INC · Health Care
Bain Capital Life Sciences Investors, LLC reported holding 7,171,910 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$23.9M, representing 1.64% of its reported portfolio and ranking #14 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Bain Capital Life Sciences Investors, LLC's CCCC position evolved
Bain Capital Life Sciences Investors, LLC first disclosed a stake in CCCC in Q3 2023 at 1,642,210 shares (US$3.1M). The position peaked in Q2 2026 at 7,171,910 shares, worth US$33.5M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 7,171,910 shares valued at US$23.9M. Notable position changes include a 30% trim in Q1 2024 (shares fell 43% over the following quarter), a 545% increase in Q4 2025 (shares rose 38% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.64M | $3.05M | New |
| Q4 2023 | 1.64M | $9.28M | Hold |
| Q1 2024 | 1.14M | $9.33M | Reduce |
| Q2 2024 | 1.11M | $5.14M | Reduce |
| Q3 2024 | 1.11M | $6.34M | Hold |
| Q4 2024 | 1.11M | $4.00M | Hold |
| Q1 2025 | 1.11M | $1.78M | Hold |
| Q2 2025 | 1.11M | $1.59M | Hold |
| Q3 2025 | 1.11M | $2.47M | Hold |
| Q4 2025 | 7.17M | $13.70M | Add |
| Q1 2026 | 7.17M | $18.86M | Hold |
| Q2 2026 | 7.17M | $33.49M | Hold |
| Q3 2026 | 7.17M | $23.88M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Soleus Capital Management, L.P. (US$15.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- RA CAPITAL MANAGEMENT, L.P. 8.00M sh · $37.36M · Q2 2026
- Lynx1 Capital Management LP 7.33M sh · $34.22M · Q2 2026
- Soleus Capital Management, L.P. 3.38M sh · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.45M sh · $11.50M · Q3 2026
- Ikarian Capital, LLC 2.43M sh · $11.36M · Q2 2026
- STEMPOINT CAPITAL LP 3.29M sh · $10.97M · Q3 2026
- HighVista Strategies LLC 873.28K sh · $2.91M · Q3 2026
- PLATINUM INVESTMENT MANAGEMENT LTD 577.53K sh · $1.92M · Q3 2026
- Squadron Capital Management LLC 400.00K sh · $1.87M · Q2 2026
- Seven Fleet Capital Management LP 381.17K sh · $1.78M · Q2 2026
More on Bain Capital Life Sciences Investors, LLC
FAQ
How long has Bain Capital Life Sciences Investors, LLC held CCCC?
Bain Capital Life Sciences Investors, LLC has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in CCCC?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 7.17M shares of CCCC (C4 THERAPEUTICS INC), valued at $23.88M, representing 1.64% of its reported portfolio and ranking #14.
Has Bain Capital Life Sciences Investors, LLC been buying or selling CCCC?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in CCCC. The position peaked in Q2 2026 at 7.17M shares.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Soleus Capital Management, L.P., among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.